Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.84 USD | -4.01% | -8.09% | -22.50% |
May. 09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
May. 09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Evolution of the average Target Price on Intellia Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Intellia Therapeutics, Inc.
Canaccord Genuity | |
Wolfe Research | |
Morgan Stanley | |
Oppenheimer | |
Goldman Sachs | |
RBC Capital Markets | |
Wedbush | |
Barclays | |
Chardan Research | |
Citigroup | |
BMO Capital | |
Raymond James | |
JPMorgan Chase | |
Bernstein | |
Baird | |
Credit Suisse | |
EF Hutton | |
Cantor Fitzgerald | |
SVB Securities LLC | |
JMP Securities | |
Wells Fargo Securities | |
Piper Sandler | |
BofA Securities | |
Guggenheim | |
Brookline Capital Markets | |
William Blair & Co. | |
Cowen | |
HC Wainwright | |
Stifel Nicolaus | |
Chardan | |
Truist Securities | |
Roth Capital Partners | |
Jefferies & Co. |
EPS Revisions
- Stock Market
- Equities
- NTLA Stock
- Consensus Intellia Therapeutics, Inc.